SentoClone Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
28
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
SentoClone General Information
Description
Operator of a medical research company intended to fight cancer. The company develops immunotherapy where the immune system is activated and strengthened to fight cancer, enabling healthcare providers to treat cancer based on the ex vivo cultivation and activation of T-cells.
Contact Information
Website
www.sentoclone.comCorporate Office
- Allen 5
- 172 66 Sundbyberg
- Sweden
Corporate Office
- Allen 5
- 172 66 Sundbyberg
- Sweden
SentoClone Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SentoClone Patents
SentoClone Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2009270434-A1 | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | Active | 18-Jul-2008 | ||
| AU-2009270434-B2 | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | Inactive | 18-Jul-2008 | ||
| CA-2730050-A1 | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | Inactive | 18-Jul-2008 | ||
| EP-2364163-A1 | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | Active | 18-Jul-2008 | ||
| EP-2364163-B1 | Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | Inactive | 18-Jul-2008 | C12N5/0636 |
SentoClone Signals
SentoClone Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SentoClone FAQs
-
When was SentoClone founded?
SentoClone was founded in 2004.
-
Where is SentoClone headquartered?
SentoClone is headquartered in Sundbyberg, Sweden.
-
What is the size of SentoClone?
SentoClone has 28 total employees.
-
What industry is SentoClone in?
SentoClone’s primary industry is Drug Discovery.
-
Is SentoClone a private or public company?
SentoClone is a Private company.
-
What is SentoClone’s current revenue?
The current revenue for SentoClone is .
-
Who are SentoClone’s investors?
Vinnova has invested in SentoClone.
-
When was SentoClone acquired?
SentoClone was acquired on 01-Jan-2010.
-
Who acquired SentoClone?
SentoClone was acquired by Sinorda Biomedicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process